These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28192098)

  • 1. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
    Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
    J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
    Valiulienė G; Vitkevičienė A; Navakauskienė R
    Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
    Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
    Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of CD11b transcription by decreasing PRC2 and increased acH4 level during ATRA-induced HL-60 differentiation.
    Tang H; Chen F; Tan Q; Tan S; Liu L; Zhang F
    Acta Biochim Biophys Sin (Shanghai); 2009 Jul; 41(7):588-93. PubMed ID: 19578722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy.
    Valiulienė G; Treigytė G; Savickienė J; Matuzevičius D; Alksnė M; Jarašienė-Burinskaja R; Bukelskienė V; Navakauskas D; Navakauskienė R
    Biomed Pharmacother; 2016 Apr; 79():62-70. PubMed ID: 27044813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High histone acetylation and decreased polycomb repressive complex 2 member levels regulate gene specific transcriptional changes during early embryonic stem cell differentiation induced by retinoic acid.
    Lee ER; Murdoch FE; Fritsch MK
    Stem Cells; 2007 Sep; 25(9):2191-9. PubMed ID: 17525233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
    Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
    Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Borutinskaitė V; Virkšaitė A; Gudelytė G; Navakauskienė R
    Leuk Lymphoma; 2018 Feb; 59(2):469-478. PubMed ID: 28641467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells.
    Hennig D; Müller S; Wichmann C; Drube S; Pietschmann K; Pelzl L; Grez M; Bug G; Heinzel T; Krämer OH
    Br J Cancer; 2015 Jan; 112(2):329-37. PubMed ID: 25514379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.